Clinical benefits of metformin in gynecologic oncology (Review)

Imai,Atsushi; Ichigo,Satoshi; Matsunami,Kazutoshi; Takagi,Hiroshi; Yasuda,Keigo

doi:10.3892/ol.2015.3262

Clinical benefits of metformin in gynecologic oncology (Review)

Authors:
- Atsushi Imai
- Satoshi Ichigo
- Kazutoshi Matsunami
- Hiroshi Takagi
- Keigo Yasuda
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Matsunami General Hospital, Kasamatsu, Gifu 501‑6062, Japan, Department of Endocrinology and Internal Medicine, Matsunami General Hospital, Kasamatsu, Gifu 501‑6062, Japan
Published online on: May 25, 2015 https://doi.org/10.3892/ol.2015.3262
Pages: 577-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evidence has suggested that diabetes may contribute to the initiation and progression of specific types of cancer. Metformin, a biguanide, has become the preferred first‑line therapy for the treatment of type 2 diabetes. Metformin is inexpensive, has a proven safety profile and is able to be safely combined with additional antidiabetic agents. In addition to the well‑established antidiabetic effects of metformin, there has also been notable interest in its antitumor properties. The present review discusses the emerging role of metformin as an example of an existing drug, used worldwide in the treatment of diabetes, which has been demonstrated to exert significant in vitro and in vivo anticancer activities and has thus been investigated in clinical trials. In gynecologic oncology, metformin has been suggested to exhibit significant treatment efficacy against endometrial cancer. Three studies have demonstrated the potential therapeutic effects of metformin on the survival outcome of patients with ovarian cancer and in ovarian cancer prevention. However, this evidence was based on observational studies. Metformin has been shown to exert no statistically significant beneficial effect on cervical cancer incidence or mortality. By cancer site, the current limited insights highlight the need for clinical investigations and better‑designed studies, along with evaluation of the effects of metformin on cancer at other sites.

View Figures

View References

1	Noto H, Goto A, Tsujimoto T, Osame K and Noda M: Latest insights into the risk of cancer in diabetes. J Diabetes Investig. 4:225–232. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sen S, He Y, Koya D and Kanasaki K: Cancer biology in diabetes. J Diabetes Investig. 5:251–264. 2014. View Article : Google Scholar : PubMed/NCBI
3	Srokowski TP, Fang S, Hortobagyi GN and Giordano SH: Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 27:2170–2176. 2009. View Article : Google Scholar : PubMed/NCBI
4	Chodick G, Heymann AD, Rosenmann L, Green MS, Flash S, Porath A, Kokia E and Shalev V: Diabetes and risk of incident cancer: A large population-based cohort study in Israel. Cancer Causes Control. 21:879–887. 2010. View Article : Google Scholar : PubMed/NCBI
5	Noto H, Tsujimoto T and Noda M: Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Investig. 2:24–33. 2012. View Article : Google Scholar
6	Suissa S and Azoulay L: Metformin and cancer: Mounting evidence against an association. Diabetes Care. 37:1786–1788. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW and Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia. 52:1732–1744. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, et al: Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 33:1997–2003. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lind M, Fahlén M, Eliasson B and Odén A: The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes. 6:53–59. 2012. View Article : Google Scholar : PubMed/NCBI
10	Weinstein D, Simon M, Yehezkel E, Laron Z and Werner H: Insulin analogues display IGF1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 25:41–49. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdòttir S and Steineck G: Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation. Acta Oncol. 50:685–693. 2011. View Article : Google Scholar : PubMed/NCBI
12	Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P and Brand-Miller JC: Glycemic index, glycemic load and chronic disease risk - a meta-analysis of observational studies. Am J Clin Nutr. 87:627–637. 2008.PubMed/NCBI
13	Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S, et al: Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): Analysis of six prospective cohorts. PLoS Med. 6:e10002012009. View Article : Google Scholar : PubMed/NCBI
14	Abe R and Yamagishi S: AGE-RAGE system and carcinogenesis. Curr Pharm Des. 14:940–945. 2008. View Article : Google Scholar : PubMed/NCBI
15	Malek M, Aghili R, Emami Z and Khamseh M: Risk of cancer in diabetes: The effect of metformin. ISRN Endocrinol. 2013:6369272013. View Article : Google Scholar : PubMed/NCBI
16	Pulito C, Sanli T, Rana P, Muti P, Blandino G and Strano S: Metformin: On ongoing journey across diabetes, cancer therapy and prevention. Metabolites. 3:1051–1075. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, et al: Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol. 209:e1–e24. 2013. View Article : Google Scholar
18	Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA: Metformin: Multi-faceted protection against cancer. Oncotarget. 2:896–917. 2011.PubMed/NCBI
19	Dowling RJ, Goodwin PJ and Stambolic V: Understanding the benefit of metformin use in cancer treatment. BMC Med. 9:332011. View Article : Google Scholar : PubMed/NCBI
20	Engelman JA and Cantley LC: Chemoprevention meets glucose control. Cancer Prev Res (Phila). 3:1049–1052. 2010. View Article : Google Scholar : PubMed/NCBI
21	Fogarty S and Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 1804:581–591. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kubota T: Update in polycystic ovary syndrome: New criteria of diagnosis and treatment in Japan. Reprod Med Biol. 12:71–77. 2013. View Article : Google Scholar : PubMed/NCBI
23	Owen MR, Doran E and Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
24	Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and Viollet B: Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 120:2355–2369. 2010. View Article : Google Scholar : PubMed/NCBI
25	Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
26	Shackelford DB and Shaw RJ: The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer. 9:563–575. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
28	Saeedi R, Parsons HL, Wambolt RB, Paulson K, Sharma V, Dyck JR, Brownsey RW and Allard MF: Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol. 294:H2497–H2506. 2008. View Article : Google Scholar : PubMed/NCBI
29	Treins C, Murdaca J, Van Obberghen E and Giorgetti-Peraldi S: AMPK activation inhibits the expression of HIF-1alpha induced by insulin and IGF-1. Biochem Biophys Res Commun. 342:1197–1202. 2006. View Article : Google Scholar : PubMed/NCBI
30	Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN and Bruchim I: n vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
31	Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
32	Alimova I, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest n vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
33	Franciosi M, Lucisano G, Lapice E, Strippoli G, Pellegrini F and Nicolucci A: Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
34	Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H and Viberti GADOPT Study Group and RECORD Steering Committee: Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 53:1838–1845. 2010.
35	Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN and Mantzoros CS: Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 60:1363–1371. 2010. View Article : Google Scholar : PubMed/NCBI
36	Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W, Pratoomsoot C, Saokeaw S and Sruamsiri R: The effects of metformin on ovarian cancer: A systematic review. Int J Gynecol Cancer. 23:1544–1551. 2013. View Article : Google Scholar : PubMed/NCBI
37	Erices R, Bravo M, Gonzalez P, Oliva B, Racordon D, Garrido M, Ibañez C, Kato S, Brañes J, Pizarro J, et al: Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci. 20:1433–1446. 2013. View Article : Google Scholar : PubMed/NCBI
38	Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity n vivo. Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
39	Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M and Gotlieb WH: Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the BCL-2 family proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
40	Kim TH, Suh DH, Kim MK and Song YS: Metformin against cancer stem cells through the modulation of energy metabolism: Special considerations on ovarian cancer. Biomed Res Int. 2014:1327022014.PubMed/NCBI
41	Xiao X, He Q, Lu C, Werle KD, Zhao RX, Chen J, Davis BC, Cui R, Liang J and Xu ZX: Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol. 127:249–255. 2012. View Article : Google Scholar : PubMed/NCBI
42	Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL and Einstein MH: Metformin use and endometrial cancer survival. Gynecol Oncol. 132:236–240. 2014. View Article : Google Scholar : PubMed/NCBI
43	Siegal R, Ward E, Browley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
44	Fader AN, Arriba LN, Frasure HE and Von Gruenigen VE: Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 114:121–127. 2009. View Article : Google Scholar : PubMed/NCBI
45	Gunter M, Hoover D, Yu H, Wassertheil-Smoller S, Manson J, Li J, Harris T, Rohan T, Xue X, Ho G, et al: A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 17:921–929. 929. View Article : Google Scholar
46	Friberg E, Orsini N, Mantzoros CS and Wolk A: Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 50:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI
47	Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL: Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI
48	Ko E, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA and Bae-Jump V: Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
49	Becker C, Jick SS, Meier CR and Bodmer M: Metformin and the risk of endometrial cancer: A case-control analysis. Gynecol Oncol. 129:565–569. 2013. View Article : Google Scholar : PubMed/NCBI
50	Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
51	Tan B, Adya R, Chen J, Lehnert H, Saint Cassia LJ and Randeva HS: Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 96:808–816. 2012. View Article : Google Scholar
52	Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA and Bae-Jump VL: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 125:458–469. 2012. View Article : Google Scholar : PubMed/NCBI
53	Hardie DG, Ross FA and Hawley SA: AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 13:251–262. 2012. View Article : Google Scholar : PubMed/NCBI
54	Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012.PubMed/NCBI
55	Shao R, Li X, Feng Y, Lin JF and Billig H: Direct effects of metformin in the endometrium: A hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res. 33:412014. View Article : Google Scholar : PubMed/NCBI
56	Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K and Murakami T: Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 14:532014. View Article : Google Scholar : PubMed/NCBI
57	Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I and Werner H: Metformin downregulates the insulin/IGF1 signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One. 8:e615372013. View Article : Google Scholar : PubMed/NCBI
58	Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
59	Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
60	Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
61	Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst J, et al: Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 55:2593–2603. 2012. View Article : Google Scholar : PubMed/NCBI
62	Zhang ZJ and Li S: The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 16:707–710. 2014. View Article : Google Scholar : PubMed/NCBI
63	Costello M, Shrestha B, Eden J, Johnson NP and Sjoblom P: Metformin versus oral contraceptive pill in polycystic ovary syndrome: A cochrane review. Hum Reprod. 22:1200–1209. 2007. View Article : Google Scholar : PubMed/NCBI
64	Costello M, Shrestha B, Eden J, Sjoblom P and Johnson N: Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 24:CD0055522007.